Organovo Holdings Inc (NYSEMKT:ONVO) Jumps 4% On Business Update Print
By William Kent   
Friday, 13 March 2015 15:42
Organovo Holdings Inc (NYSEMKT:ONVO)’s shares climbed up 4% to $4.60 following the company updated about its business. The company said that it extremely excited about their early commercial success of exVive3D" Human Liver Tissue and they continue to believe that it has a strong commercial future in front of it. The company said in a market update that they believe that as when they will penetrate the toxicology market, their exVive3D" Human Liver Tissue and service will grow into the tens of millions in annual revenue, and has $100M+ revenue potential in the future as they pursue diligent sales and marketing efforts (inside of a total addressable market of over $1B). 

In addition to having excellent operational execution, Organovo is also financially strong.  Balance sheet of the company is strong with no debt, more than $50 million in cash on hand, and a prior quarter burn rate that annualized at approximately $19 million per year. Organovo's Board and management team are focused on executing the goals and remain confident in the Company's technology and team.  The Company has hit every milestone it has described to investors on a timely basis since going public in 2012. 

Organovo designs create functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company had recently launched its initial product of the planned exVive3D" portfolio offering, 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products are in development, with anticipated release for an exVive3DTM Human Kidney Tissue in the latter half of calendar year 2016.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!